Sun Pharma Advanced Research Company Limited - Asset Resilience Ratio
Sun Pharma Advanced Research Company Limited (SPARC) has an Asset Resilience Ratio of 0.64% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Sun Pharma Advanced Research Company Lim (SPARC) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Sun Pharma Advanced Research Company Limited's Asset Resilience Ratio has changed over time. See Sun Pharma Advanced Research Company Lim balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Sun Pharma Advanced Research Company Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SPARC market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs20.60 Million | 0.64% |
| Total Liquid Assets | Rs20.60 Million | 0.64% |
Asset Resilience Insights
- Limited Liquidity: Sun Pharma Advanced Research Company Limited maintains only 0.64% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sun Pharma Advanced Research Company Limited Industry Peers by Asset Resilience Ratio
Compare Sun Pharma Advanced Research Company Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Sun Pharma Advanced Research Company Limited (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Sun Pharma Advanced Research Company Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.70% | Rs23.60 Million ≈ $255.23K |
Rs3.36 Billion ≈ $36.29 Million |
-28.77pp |
| 2024-03-31 | 29.47% | Rs1.52 Billion ≈ $16.42 Million |
Rs5.15 Billion ≈ $55.70 Million |
-32.31pp |
| 2023-03-31 | 61.78% | Rs5.13 Billion ≈ $55.47 Million |
Rs8.30 Billion ≈ $89.77 Million |
+57.62pp |
| 2022-03-31 | 4.16% | Rs116.65 Million ≈ $1.26 Million |
Rs2.80 Billion ≈ $30.29 Million |
+1.37pp |
| 2021-03-31 | 2.80% | Rs64.25 Million ≈ $694.86K |
Rs2.30 Billion ≈ $24.84 Million |
-0.32pp |
| 2020-03-31 | 3.12% | Rs84.91 Million ≈ $918.26K |
Rs2.73 Billion ≈ $29.48 Million |
-49.73pp |
| 2019-03-31 | 52.85% | Rs2.11 Billion ≈ $22.77 Million |
Rs3.98 Billion ≈ $43.09 Million |
+17.22pp |
| 2018-03-31 | 35.62% | Rs1.10 Billion ≈ $11.90 Million |
Rs3.09 Billion ≈ $33.40 Million |
+6.48pp |
| 2017-03-31 | 29.14% | Rs798.60 Million ≈ $8.64 Million |
Rs2.74 Billion ≈ $29.64 Million |
+25.60pp |
| 2014-03-31 | 3.54% | Rs65.00 Million ≈ $702.97K |
Rs1.84 Billion ≈ $19.85 Million |
-42.83pp |
| 2013-03-31 | 46.37% | Rs969.06 Million ≈ $10.48 Million |
Rs2.09 Billion ≈ $22.60 Million |
-- |
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia th… Read more